These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 18024853)

  • 1. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
    Risérus U; Sprecher D; Johnson T; Olson E; Hirschberg S; Liu A; Fang Z; Hegde P; Richards D; Sarov-Blat L; Strum JC; Basu S; Cheeseman J; Fielding BA; Humphreys SM; Danoff T; Moore NR; Murgatroyd P; O'Rahilly S; Sutton P; Willson T; Hassall D; Frayn KN; Karpe F
    Diabetes; 2008 Feb; 57(2):332-9. PubMed ID: 18024853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
    Chen W; Wang LL; Liu HY; Long L; Li S
    Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):240-6. PubMed ID: 18684227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
    Olson EJ; Pearce GL; Jones NP; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
    Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA
    Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
    Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
    Coll T; Alvarez-Guardia D; Barroso E; Gómez-Foix AM; Palomer X; Laguna JC; Vázquez-Carrera M
    Endocrinology; 2010 Apr; 151(4):1560-9. PubMed ID: 20185762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
    Kannisto K; Chibalin A; Glinghammar B; Zierath JR; Hamsten A; Ehrenborg E
    Int J Mol Med; 2006 Jan; 17(1):45-52. PubMed ID: 16328010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta.
    Sprecher DL
    Am J Cardiol; 2007 Dec; 100(11 A):n20-4. PubMed ID: 18047848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis.
    Pesant M; Sueur S; Dutartre P; Tallandier M; Grimaldi PA; Rochette L; Connat JL
    Cardiovasc Res; 2006 Feb; 69(2):440-9. PubMed ID: 16337160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function.
    Karpe F; Ehrenborg EE
    Curr Opin Lipidol; 2009 Aug; 20(4):333-6. PubMed ID: 19512923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
    Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
    Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of (ω-3) polyunsaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human peripheral blood mononuclear cells and HepG2 cells.
    Radler U; Stangl H; Lechner S; Lienbacher G; Krepp R; Zeller E; Brachinger M; Eller-Berndl D; Fischer A; Anzur C; Schoerg G; Mascher D; Laschan C; Anderwald C; Lohninger A
    Ann Nutr Metab; 2011; 58(2):133-40. PubMed ID: 21540583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.
    Sprecher DL; Massien C; Pearce G; Billin AN; Perlstein I; Willson TM; Hassall DG; Ancellin N; Patterson SD; Lobe DC; Johnson TG
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):359-65. PubMed ID: 17110604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
    Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARδ activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference.
    Feng YZ; Nikolić N; Bakke SS; Boekschoten MV; Kersten S; Kase ET; Rustan AC; Thoresen GH
    Arch Physiol Biochem; 2014 Feb; 120(1):12-21. PubMed ID: 23991827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome and the hepatic fatty acid drainage hypothesis.
    Berge RK; Tronstad KJ; Berge K; Rost TH; Wergedahl H; Gudbrandsen OA; Skorve J
    Biochimie; 2005 Jan; 87(1):15-20. PubMed ID: 15733731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss.
    Corpeleijn E; Mensink M; Kooi ME; Roekaerts PM; Saris WH; Blaak EE
    Obesity (Silver Spring); 2008 May; 16(5):1025-32. PubMed ID: 18309299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
    Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
    Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta.
    Ehrenborg E; Krook A
    Pharmacol Rev; 2009 Sep; 61(3):373-93. PubMed ID: 19805479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.